More Impact, Together: Varian and Siemens Healthineers Portfolios Highlight More Impact, Innovations and More Breakthroughs Throughout Cancer Care Journey at ESTRO 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Varian, a Siemens Healthineers company, will showcase an integrated portfolio designed to streamline workflows, and aiming to enhance patient experience and improve patient outcomes from screening to survivorship at the 2025 European Society for Radiotherapy and Oncology (ESTRO) annual meeting, May 2-6, in Vienna, Austria.
'Our accelerated pace of innovation demonstrates that we offer more impact, together, in our mission toward a world without fear of cancer.'
Share
'As part of Siemens Healthineers, we are uniquely positioned to transform cancer and beyond, and we are supercharging our commitment to patient-centricity with greater scale and impact,' said Arthur Kaindl, Head of Varian. 'Our accelerated pace of innovation demonstrates that we offer more impact, together, in our mission toward a world without fear of cancer.'
Varian and Siemens Healthineers will announce ground-breaking technologies empowering access to MRI for radiotherapy practices with the goal of establishing MRI in daily clinical routine, as well as showcase how its RapidArc Dynamic solution enables greater efficiency, precision, and flexibility in treatment planning and delivery at its booth (ESTRO #250), Friday, May 2, at 19:04 CEST.
Varian's RapidArc Dynamic solution, available as an optional feature for the latest versions of Eclipse treatment planning software and the TrueBeam radiotherapy delivery platform, is powered by next-generation algorithms, combining a dynamic collimator and modulated ports working seamlessly in a single arc treatment field to provide clinicians with supreme control for optimal dose delivery.
More innovations, together
With the latest version of the ARIA CORE oncology management solution, Varian has strengthened integration with its software solutions, Noona and ARIA CORE Insights, to provide a seamless user experience and help streamline clinical workflows. Varian will also introduce ARIA CORE Automations, enabling users to automate workflows within ARIA CORE to drive efficiency and establish standardization.
As an example of Varian and Siemens Healthineers' expanded strength as one team, Siemens Healthineers will be introducing Oncology Exchange, which improves integration by automatically transferring ARIA CORE prescription information to setup and configure the CT simulator.
Reflecting the growing use of MRI in radiation therapy, Siemens Healthineers will present dedicated deep-learning algorithms for MRI autocontouring of brain metastases, and autocontouring of brain organs at risk – optimized for use with HyperArc high-definition radiotherapy.
More breakthroughs, together
With almost 40 Varian-supported abstracts accepted as part of ESTRO 2025, Varian is proud to collaborate with research leaders in the field.
Included in this year's ESTRO program is evidence generated by Varian-sponsored clinical trials and consortium members underscoring the value of Varian's HyperSight imaging, an optional feature for selected Varian linacs, and Varian's Ethos adaptive radiotherapy system.
'We recognize that every step of the cancer care journey needs to be effective and efficient, and delivered at the highest possible levels of clinical confidence and patient experience,' Kaindl said. 'We are committed to driving sustainable innovations that introduce new and enhanced tools in the fight against cancer.'
© 2025 VARIAN MEDICAL SYSTEMS, INC. All trademarks are the property of their respective owners.
QR700022422
About Varian
At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 75 years, Varian has developed, built, and delivered innovative technologies and solutions that help care providers around the globe treat millions of patients each year. Today, as a Siemens Healthineers company, we support every step of the cancer care journey – from screening to survivorship. From advanced imaging and radiation therapy to comprehensive software and services, to interventional radiology, we are harnessing the power of our perspective while also pursuing clinical research to create a more efficient, and more personalized care pathway. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
MRI Software Completes Acquisition of Anacle, a leading Singapore-based provider of Property and Facilities Management Solutions
Acquisition extends MRI's footprint in Asia; expands offerings for commercial real estate owners, operators, and tenants; drives scale with AI-powered innovations SYDNEY, June 10, 2025 /PRNewswire/ -- MRI Software, a global leader in real estate solutions and services, announced that it has completed its acquisition of Singapore-based Anacle Systems Limited, a pioneer in commercial property management, facilities, digital workplace, energy, and asset management solutions. The acquisition delivers expanded capabilities and scale for the commercial, occupier, and residential markets across Asia Pacific, including the public and private sectors. The deal was initially announced in March and the take-private transaction has been completed. A Game-Changer for APAC's PropTech Ecosystem "This acquisition marks a major milestone in our APAC growth journey," said David Bowie, Executive Managing Director, APAC, MRI Software. "By combining Anacle's deep expertise in property management, smart infrastructure, sustainability, and government-grade lifecycle asset management with MRI's open, AI-powered platform, we are unlocking new levels of innovation, compliance, and operational insight for our clients." The strategic collaboration deepens MRI's longstanding client relationships in Singapore and expands its presence across Asia via Anacle's trusted client base and solutions tailored for complex, regulated environments. At the same time, Anacle clients gain access to MRI's broader global ecosystem—spanning property management, document intelligence, leasing, and analytics capabilities. Complementary Strengths Delivering Immediate Client Value Anacle's products will be enhanced with MRI's broader real estate and energy technology offerings. Together, the combined portfolio delivers solutions across Asia-Pacific for all property sectors. "This is a powerful collaboration," said Alex Lau, CEO of Anacle. "MRI brings the operational scale, innovation roadmap, and trusted global presence that will empower us to accelerate our product vision and deliver even more benefits to our clients across Asia. We're proud to join an organization that shares our dedication to the industry and aligns with our core values." An Enhanced Regional Presence with Global Support Anacle's headquarters in Singapore and diverse customer base across Hong Kong, Japan, Malaysia, Taiwan, China and other Asian countries expand MRI's presence in the region, giving clients across Asia-Pacific access to more regional talent, increased investment and product localisation—all while maintaining continuity of service. Anacle will continue to support its clients without interruption. About MRI SoftwareMRI Software is a leading provider of real estate software and services that transform the way communities live, work and play. MRI's open and connected, AI-powered platform enables owners, operators, agents and occupiers in commercial and residential property organisations to innovate in rapidly changing markets. A trailblazer in the PropTech industry, MRI serves more than 45,000 organisations across 170 countries. Through innovative solutions and a rich partner ecosystem, MRI gives real estate companies the freedom to realise their vision of building thriving communities and stronger businesses. MRI became one of the first real estate software providers to serve Australia and New Zealand in 1995 and continues to grow its client and employee footprint throughout the APAC region. For more information, please visit Media Contact Amber KeoghCommunications Snr Manager, MRI Software View original content: SOURCE MRI Software
Yahoo
10 hours ago
- Yahoo
ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory
We came across a bullish thesis on ClearPoint Neuro, Inc. (CLPT) on M.V. Cunha's Substack. In this article, we will summarize the bulls' thesis on CLPT. ClearPoint Neuro, Inc. (CLPT)'s share was trading at $13.93 as of 6th June. A medical doctor surrounded by advanced technology in the operating room. ClearPoint Neuro is transforming from a surgical tools provider into a critical platform company enabling the next generation of neurological treatments. In the first quarter of 2025, revenue grew 31 percent year-over-year to 8.5 million dollars, led by the rapid adoption of its SmartFrame operating room system, which increased 70 percent and allows hospitals to use ClearPoint technology in standard surgical settings. This expansion seeds a larger installed base and drives high-margin recurring revenue from disposable instruments. The biologics and drug delivery segment generated 4.7 million dollars in revenue, growing 9 percent year-over-year, and is supported by more than 60 active partnerships with gene and cell therapy developers. As these therapies move toward commercial use, ClearPoint's role as the enabling delivery infrastructure could become its most profitable revenue stream, with each procedure generating over 20,000 dollars in high-margin recurring revenue. Meanwhile, the company is intentionally moving away from capital equipment sales, which declined 63 percent, in favor of a subscription-based model that provides predictable recurring revenue. Operating cash burn fell 35 percent in 2024, with expenses rising 29 percent in the latest quarter due to targeted investments in preclinical services, therapy support, and device innovation. ClearPoint closed the quarter with 12.4 million dollars in cash and access to up to 105 million dollars in financing, providing sufficient capital to reach financial breakeven without near-term equity dilution. While risks around execution, partner dependency, and regulatory pacing remain, ClearPoint's embedded position across neurological therapy development offers investors a unique opportunity to benefit from a long-term transformation into the backbone of next-generation brain treatments. Previously, we highlighted a on ClearPoint Neuro from northeasternsvf in January 2025, which emphasized its unique position as the only FDA-cleared, MRI-guided neurosurgical platform enabling precise delivery of CNS gene and cell therapies. That thesis focused on the company's expanding biopharma partnerships, operating room penetration through SmartFrame OR, and its path to profitability via high-margin disposables. ClearPoint Neuro, Inc. (CLPT) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held CLPT at the end of the first quarter which was 13 in the previous quarter. While we acknowledge the risk and potential of CLPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CLPT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Indianapolis Star
10 hours ago
- Indianapolis Star
Caitlin Clark injury update: When will Fever star return? 'We're gonna play the long game'
INDIANAPOLIS – Caitlin Clark will not play in Tuesday's game at Atlanta, Fever coach Stephanie White said on Monday. Clark's status for the game, which come just over two weeks after she suffered a quad strain, was previously up in the air. Clark didn't rule out playing in the game in her availability on June 3, but said she would need to be re-evaluated and left it up to the Fever's medical staff to make the final decision. Now, that question has been answered. "Not for tomorrow, no," White said Monday when asked if Clark would be available on Tuesday. Personal touches, secret messages: Behind the scenes of making Caitlin Clark's new Wilson basketballs Clark suffered a quad strain sometime during the Fever's game against the New York Liberty on May 24, though she couldn't pinpoint the specific play it happened. She reported some pain after the game and got an MRI, which showed a strain in her left quad. 'Obviously, adrenaline covers up a lot of stuff when you're in the heat of battle,' Clark said during her media availability on June 3. 'And after the game, I had some pain, and then we got an MRI, and that kind of gave me the result that I didn't want to see. But, you know, those types of things don't lie.' Clark's original timeline was that she would be out for two weeks before she would be re-evaluated, setting her re-evaluation date at June 8. She was evaluated this weekend and allowed to begin some aspects of practice again, White said, but not necessarily cleared for basketball activities at the highest level. "I don't know if cleared is the right word, I mean, she's ready to start ramping back up," White said. "But it's completely different when you're just doing 1-on-1 workouts, and when you're out there in 5-on-5, getting up and down the floor, moving laterally. So she's been allowed to do some practicing, not everything. And we're gonna be smart, and we're gonna be cautious, and we're gonna play the long game." Clark participated in the portion of practice open to media Monday afternoon, which were shooting drills from midrange and 3-point range. They went around the arc as a team, making shots from each corner, each wing and the top of the key. Clark didn't seem limited in that portion of practice, running for rebounds and shooting as normal. But shooting drills are much different than actual practice — both in the amount of contact and the intricacies of it. "It's one thing to do some shooting drills," White said. "It's another thing to get out there on the floor, get back into movement patterns, rhythm, timing, and so that's what part of, you know, picking and choosing things that they can be in in practice, so that we can see their progression." White did not provide a specific timeline for Clark's return to the court. The Fever play at Atlanta on Tuesday, then return to Indianapolis and a have a few days off before playing the New York Liberty on Saturday. No, the Fever star will miss her fifth straight game as she recovers from a quad injury. Coach Stephanie White confirmed Monday that Clark would not play on Tuesday.
